Hiroyuki Mineta

Hiroyuki Mineta

Auto-generated profile, based on publicly available information

Hiroyuki Mineta

Hamamatsu University School of Medicine

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Oral Oncology
Verified
Journal Article
Closed access
HMH. Mineta
H. Mineta
KMK. Miura
K. Miura
STS. Takebayashi
S. Takebayashi
YUY. Ueda
Y. Ueda
KMK. Misawa
K. Misawa
MDM. Dictor
M. Dictor

23 February 2016 in Acta Oto-Laryngologica
Verified
Journal Article
Open access
PDF file
SEShiori Endo
Shiori Endo
KMKunihiro Mizuta
Kunihiro Mizuta
GTGoro Takahashi
Goro Takahashi
HNHiroshi Nakanishi
Hiroshi Nakanishi
TYTakashi Yamatodani
Takashi Yamatodani
HMHiroyuki Mineta
Hiroyuki Mineta
Conclusions This study suggests that long-term ventilation tube insertion is the first-choice surgical treatment for a ‘sniff-type’ patulous Eustachian tube (PET). When treating a refractory PET, it is important to determine whether the patient had a habitual sniff. Objectives PET patients were divided into two groups: patients with a habitual sniff (sniff-type PET) and those without a habitual sniff (non-sniff-type PET). This study examined the effects of ventilation tube insertion or silicone plug insertion in each group. Methods Surgical procedures such as ventilation tube insertion or trans-tympanic silicone plug insertion were performed for these patients. Tubotympanoaero-dynamic graphy (TTAG) was also performed to determine the mechanisms underlying these treatments. Results There were 11 cases (17 ears) of sniff-type PET and 20 cases (27 ears) of non-sniff-type PET. An improvement in symptoms was found in 72.7% of the patients who underwent silicone plug insertion (66.7% for sniff-type PET and 74.1% for non-sniff-type PET) and in 90.9% of the patients who underwent ventilation tube insertion for sniff-type PET. In TTAG assessments, many sniff-type PET patients showed significant synchronous changes at high levels of pressure (over 40 daPa) in the external auditory meatus and nasopharynx when performing a slight Valsalva manoeuvre (below 200 daPa).

29 September 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
KMKiyoshi Misawa
Kiyoshi Misawa
AIAtsushi Imai
Atsushi Imai
TKTakeharu Kanazawa
Takeharu Kanazawa
MMMasato Mima
Masato Mima
SYSatoshi Yamada
Satoshi Yamada
HMHiroyuki Mineta
Hiroyuki Mineta
Differences in the biology of human papillomavirus (HPV)-associated oropharyngeal cancers (OPCs) and HPV-negative OPCs may have implications in patient management. Early detection is imperative to reduce HPV-associated OPC mortality. Circulating tumor DNA (ctDNA) can potentially serve as a biomarker for monitoring clinically relevant cancer-related genetic and epigenetic modifications. We analyzed the methylation status of 24 G protein-coupled receptor (GPCR) genes in verification (85 OPC primary samples) and validation (8 OPC ctDNA samples) studies using quantitative methylation-specific polymerase chain reaction (Q-MSP). The Q-MSP-based verification study with 85 OPC primary samples revealed the GPCR genes that were significantly associated with recurrence in high methylation groups (≥14 methylated genes) with OPC and HPV-associated OPC (p < 0.001). In the Kaplan–Meier estimate and multivariate Cox proportional hazard analyses, 13 GPCR genes were significantly related to increased recurrence in the methylation group. Furthermore, the validation study on ctDNA showed that three of these genes (Prostaglandin D2 receptor 1: PTGDR1, Prostaglandin D2 receptor 2: PTGDR2, and Prostaglandin I2 Receptor: PTGIR) had a prediction performance as emerging biomarkers. We characterized the relationship between the methylation status of GPCR genes and outcomes in HPV-associated OPC. Our results highlight the potential utility of ctDNA methylation-based detection for the clinical management of HPV-associated OPC.

11 April 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
KMKiyoshi Misawa
Kiyoshi Misawa
MMMasato Mima
Masato Mima
AIAtsushi Imai
Atsushi Imai
DMDaiki Mochizuki
Daiki Mochizuki
YMYuki Misawa
Yuki Misawa
HMHiroyuki Mineta
Hiroyuki Mineta
Staging and pathological grading systems are convenient but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). Identifying biomarkers for HNSCC that will progress and cause death is a critical research area, particularly if the biomarker can be linked to selection of patients. Therefore, to identify potential alternative prognostic markers, we investigated the methylation status of five neuropeptide gene promoters. The promoter methylation status was determined by quantitative methylation-specific PCR in 230 cases of HNSCC; 58 hypopharynx, 45 larynx, 56 oropharynx, and 71 oral cavity tumor samples were studied. The somatostatin (SST), tachykinin precursor 1 (TAC1), hypocretin neuropeptide precursor (HCRT), neuropeptide Y (NPY), and galanin (GAL) promoters were methylated in 84.3, 63.5, 32.6, 28.3, and 20.0%, respectively, of the samples. The mean number of methylated genes per sample was 2.29 (range, 0–5). Disease-free survival was lower in patients with 3–5 methylated genes than in those with 0–2 methylated genes (log-rank test, P = 0.007). In multivariate Cox proportional hazards analysis, TAC1 and GAL promoter methylation independently predicted recurrence (odds ratios 1.620, 95% confidence interval [CI] 1.018–2.578, P = 0.042, and odds ratios 1.692, 95% CI 1.063–2.694, P = 0.027, respectively). In patients with oral cancer, TAC1 methylation showed the best correlation with poor survival (odds ratio 4.427, 95% CI 1.634–12.00, P = 0.003). Similar findings were observed for HCRT and GAL in patients with laryngeal cancer and oropharyngeal cancer, respectively. In this study, we demonstrated the methylation status of the neuropeptide-encoding genes SST, TAC1, HCRT, NPY, and GAL and its relationship with recurrence and survival in HNSCC. These methylation changes may serve as potential molecular markers for defining the risk and prognosis of HNSCC.

22 October 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
KMKiyoshi Misawa
Kiyoshi Misawa
Hideya KawasakiHideya Kawasaki
Hideya Kawasaki
RMRieko Matsuo
Rieko Matsuo
KSKenichi Sugiyama
Kenichi Sugiyama
DMDaiki Mochizuki
Daiki Mochizuki
HMHiroyuki Mineta
Hiroyuki Mineta
Small cell carcinoma/neuroendocrine carcinoma (SCNEC) of the oropharynx is uncommon. Two cases of SCNEC in an 81-year-old woman and in a 54-year-old man are presented here. We have documented two cases of SCNEC arising in the oropharynx with evidence of high-risk human papillomavirus (HPV) infection. Histologically, both cases were classified as poorly differentiated SCNEC with high nuclear-to-cytoplasmic ratios and nuclear molding. Observations using a transmission electron microscope revealed membrane-bound neuroendocrine granules in some tumor cells. Both tumors expressed high levels of p16, a surrogate marker for high-risk HPV infection. HPV infection was confirmed in both cases using HPV polymerase chain reaction analysis; HPV subtype 16 was identified in one case and HPV subtype 18 in the other. SCNEC of the oropharynx is a rare and novel HPV-associated disease with neuroendocrine granules and aggressive clinical behavior. Herein, we present two cases of SCNEC, focusing on its histologic features and treatment modalities. More studies are required to elucidate the pathophysiology of HPV-associated SCNEC in different organ systems.

1 January 2003 in Oral Oncology
Verified
Journal Article
Closed access
HMH Mineta
H Mineta
KMKa Miura
Ka Miura
STS Takebayashi
S Takebayashi
KMKi Misawa
Ki Misawa
YUY Ueda
Y Ueda
JWJ Wennerberg
J Wennerberg